RADIOATIVE MICROSPHERE AND PREPARATION METHOD THEREOF
20200023088 ยท 2020-01-23
Inventors
Cpc classification
A61N5/1007
HUMAN NECESSITIES
International classification
A61K51/12
HUMAN NECESSITIES
A61N5/10
HUMAN NECESSITIES
A61B6/00
HUMAN NECESSITIES
Abstract
Provided is a radioactive microsphere including a glass sphere core. The glass sphere core includes a first seed, a second seed and a diffusion region extending inwardly from an outer surface of the glass sphere core, with the second seed distributed in the diffusion region. The first seed and the second seed become radioactive after being activated by neutrons to produce radiations including -rays or -rays, or simultaneously -rays and -rays. A preparation method of a radioactive microsphere is also provided.
Claims
1. A radioactive microsphere, comprising: a glass sphere core comprising a first seed, a second seed, and a diffusion region extending inwardly from an outer surface of the glass sphere core, wherein the second seed is distributed in the diffusion region, and the first seed and the second seed become radioactive after being activated by neutrons to produce radiations comprising -rays or -rays, or simultaneously -rays and -rays.
2. The radioactive microsphere of claim 1, further comprising a shell layer coating the glass sphere core.
3. The radioactive microsphere of claim 2, wherein the shell layer is formed by a material comprising one of an organic material and an inorganic material, or a combination thereof.
4. The radioactive microsphere of claim 1, wherein the glass sphere core comprises a radioactive therapeutic agent.
5. The radioactive microsphere of claim 1, wherein the first seed comprises one of yttrium, aluminum and silicon, or a combination thereof.
6. The radioactive microsphere of claim 1, wherein the second seed before being activated by the neutrons is at least one selected from the group consisting of: phosphorus, calcium, sodium, rhenium, scandium, lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, actinium-225, antimony-127, arsenic-74, barium-140, bismuth-210, californium-246, calcium-46, calcium-47, carbon-11, carbon-14, cesium-131, cesium-137, chromium-51, cobalt-57, cobalt-58, cobalt-60, dysprosium-165, erbium-169, fluorine-18, gallium-67, gallium-68, gold-198, holmium-166, hydrogen-3, indium-111, indium-113m, iodine-123, iodine-125, iodine-131, iridium-192, iron-59, iron-82, krypton-81m, lanthanum-140, lutetium-177, molybdenum-99, nitrogen-13, oxygen-15, palladium-103, phosphorus-32, radon-222, radium-224, rhenium-186, rhenium-188, rhodium-82, samarium-153, selenium-75, sodium-22, sodium-24, strontium-89, technetium-99m, thallium-201, xenon-127, xenon-133 and yttrium-90.
7. The radioactive microsphere of claim 3, wherein the organic material comprises an acid group, a hydroxyl group, an amine group or a biodegradable material.
8. The radioactive microsphere of claim 7, wherein the organic material is at least one selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, carboxymethyl cellulose, methyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyethylene glycol, gum arabic and a copolymer of polylactic acid and polylactic acid-glycolic acid.
9. The radioactive microsphere of claim 3, wherein the inorganic material comprises a phosphate compound, a sulfate compound, a chlorine salt compound, a nitrate compound or a borate compound.
10. The radioactive microsphere of claim 3, wherein the shell layer is further grafted with a radioactive therapeutic agent or a radioactive contrast agent.
11. A method for preparing a radioactive microsphere, comprising: heating glass powder comprising a first seed to spheroidize and form a glass sphere core; and reacting the glass sphere core with a cooling source, wherein the cooling source is a saturated liquid containing a second seed liquid phase component with a second seed diffused into the glass sphere core by being thermally activated to form a diffusion region extending inwardly from an outer surface of the glass sphere core, wherein the first seed and the second seed are radioactive after being activated by neutrons to produce radiations comprising -rays or -rays, or simultaneously -rays and -rays.
12. The method of claim 11, further comprising forming a shell layer coating the glass sphere core by a spray process.
13. The method of claim 12, wherein the shell layer is grafted with a radioactive therapeutic agent or a radioactive contrast agent.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0011]
[0012]
[0013]
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
DETAILED DESCRIPTIONS
[0022] The following embodiments are provided to illustrate the disclosure of the present disclosure. One skilled in the art can easily understand the advantages and functions after reading the disclosure of the present specification.
[0023] It shall be understood that structures, proportions, dimensions, and the like of the present disclosure are for comprehension of one skilled in the art, instead of the intention of limiting the present disclosure under specific conditions, and do not have any technical significance. Without prejudice to effects and achievable objectives of this specification, modifications of any structure, changes in the proportional relationship, or adjustments to the dimensions are included within the scope of the present disclosure without departing from the scope of the disclosure. Without any substantial alteration of technical contents, changes or adjustments to the relative relationship of the present disclosure are deemed to be within the scope of the present disclosure.
[0024] The present disclosure provides a radioactive microsphere having a complex shell-like structure with a second seed element in a diffusion region of a glass sphere core.
[0025] As shown in
[0026] In one embodiment, the radioactive microsphere 1 further includes a shell layer 300 covering the glass sphere core 100, and the material of the shell layer 300 is one of an organic material, an inorganic material, or a combination thereof.
[0027] The shell layer 300 can be coated with the organic material, one of the inorganic materials, or a combination thereof on the glass sphere core 100 by a spray method. In one embodiment, the organic material comprises an acid group, a hydroxyl group, an amine group or a biodegradable material; the inorganic material comprises a phosphate compound, a sulfate compound, a chloride compound, a nitrate compound or a borate compound.
[0028] In one embodiment, the organic material is selected from at least one of the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, carboxymethyl cellulose, methyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyethylene glycol, gum arabic and a copolymer of polylactic acid and polylactic acid-glycolic acid.
[0029] In another embodiment, the shell layer 300 is further grafted with a radiotherapeutic agent or a radioactive contrast agent.
[0030] In a specific embodiment, the glass sphere core comprises a radiotherapeutic agent. Specifically, the first seed may be yttrium. Further, the second seed used in the present disclosure may be provided in the form of an isotope suspension or an oxidized acid or an alkali oxide or a dissociable salt. There is no particular limitation as long as it can achieve separation of element by a heating, dissolving or melting procedure to provide surface treatment. For example, before neutron activation, the second seed is selected from at least one of the group consisting of phosphorus, calcium, sodium, rhenium, scandium, lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, actinium-225, antimony-127, arsenic-74, barium-140, bismuth-210, californium-246, calcium-46, calcium-47, carbon-11, carbon-14, cesium-131, cesium-137, chromium-51, cobalt-57, cobalt-58, cobalt-60, dysprosium-165, erbium-169, fluorine-18, gallium-67, gallium-68, gold-198, holmium-166, hydrogen-3, indium-111, indium-113m, iodine-123, iodine-125, iodine-131, iridium-192, iron-59, iron-82, krypton-81m, lanthanum-140, lutetium-177, molybdenum-99, nitrogen-13, oxygen-15, palladium-103, phosphorus-32, radon-222, radium-224, rhenium-186, rhenium-188, rhodium-82, samarium-153, selenium-75, sodium-22, sodium-24, strontium-89, technetium-99m, thallium-201, xenon-127, xenon-133 and yttrium-90. Said second seed is activated by neutron activation and decays into an element represented in the brackets, phosphorus (.sup.32P->.sup.32S), calcium (.sup.47Ca->.sup.47Sc; .sup.49Ca->.sup.49Sc), sodium (.sup.22Na->.sup.22Ne), rhenium (.sup.188Re->.sup.188Os), scandium (.sup.44Sc->.sup.44Ca; .sup.48Sc->.sup.48Ti; .sup.46Sc->.sup.46Ti; .sup.47Sc->.sup.47Ti), lanthanum (.sup.140La->.sup.140Ce; .sup.142La->.sup.142Ce), cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, actinium-225 (.sup.225Ac->.sup.221Fr,.sup.211Bi,.sup.14C), antimony-127 (.sup.127Sb->.sup.127Te), arsenic-74 (.sup.74As->.sup.74Ge), barium-140 (.sup.140Ba->.sup.140La), bismuth-210 (.sup.210Bi->.sup.210Po), californium-246 (.sup.246Cf->.sup.246Cm), calcium-46 (.sup.46Ca->.sup.46Sc), calcium-47 (.sup.47Ca->.sup.47Sc), carbon-11 (.sup.11C->.sup.11B), carbon-14 (.sup.14C->.sup.14N), cesium-131 (.sup.131Cs->.sup.131Xe;.sup.131Cs->.sup.131Ba), cesium-137 (.sup.137Cs->.sup.137Ba), chromium-51 (.sup.51Cr->.sup.51V), cobalt-57 (.sup.57Co->.sup.57Fe), cobalt-58 (.sup.58Co->.sup.58Fe), cobalt-60 (.sup.60Co->60Ni), dysprosium-165 (.sup.165Dy->.sup.165Ho), erbium-169 (.sup.169Er->.sup.169Tm), fluorine-18 (.sup.18F->.sup.18O), gallium-67 (.sup.67Ga->.sup.67Zn), gallium-68 (.sup.68Ga->.sup.68Zn), gold-198 (.sup.198Au->.sup.198Hg), holmium-166 (.sup.166Ho->.sup.166Er), hydrogen-3 (.sup.3H->.sup.3He), indium-111 (.sup.111In->.sup.111Cd), indium-113m (.sup.113mIn->.sup.113Sn), iodine-123 (.sup.123I->.sup.123Te), iodine-125 (.sup.125I->.sup.125Te), iodine-131 (.sup.131I->.sup.131Xe), iridium-192 (.sup.192Ir->.sup.192Os,.sup.192Po, iron-59 (.sup.59Fe->.sup.59Co), krypton-81m (.sup.81mKr->.sup.81Br), lanthanum-140 (.sup.140La->.sup.140Ce), lutetium-177 (.sup.177Lu->.sup.177Hf), molybdenum-99 (.sup.99Mo->.sup.99Tc,99Ru), nitrogen-13 (.sup.13N->.sup.13C), oxygen-15 (.sup.15O->.sup.15N), palladium-103 (.sup.103Pd->.sup.103Rh), Phosphorus-32 (.sup.32P->.sup.32S), radon-222 (.sup.222Rn->.sup.218Po), radium-224 (.sup.224Ra->.sup.220Rn,.sup.210Pb,.sup.14C), rhenium-186 (.sup.186Re->.sup.186Os,.sup.186W), rhenium-188 (.sup.188Re->.sup.188Os), samarium-153 (.sup.153Sm->.sup.153Eu), selenium-75 (.sup.75Se->.sup.75As), sodium-22 (.sup.22Na->.sup.22Ne), sodium-24 (.sup.24Na->.sup.24Mg), strontium-89 (.sup.89Sr->.sup.89Y), technetium-99m (.sup.99Tc->.sup.99Ru), thallium-201 (.sup.201Ti->.sup.201Hg), xenon-127 (.sup.127Xe->.sup.127Cs), xenon-133 (.sup.133Xe->.sup.133Cs) and yttrium-90 (.sup.99Y->.sup.99Sr).
[0031] In one embodiment, the second seed element used in the present disclosure is not limited to an isotope suspension or an oxidized acid or an alkali oxide or a dissociable salt. As long as it can be used for diagnosis, treatment, and research of diseases by intravenous, oral, or inhalation of a small amount of radioisotope preparation, according to its in vivo distribution or in vitro quantification, it can be used to provide elements of the second seed. These radionuclides have specific affinities for specific organs, bones or tissues. They emit -rays and can be passed through special photographic equipment in vitro. For example, the camera or positron tomography scanner is used to detect its distribution and metabolism in vivo. The integration of photographic equipment with computers can display images, and can be calculated and analyzed for more information. Since most diseases have physiological, biochemical, and metabolic changes in the early stages of the disease, and then structural changes occur, most of X-ray examinations, computerized tomography, etc. are used to detect physical structures. Nuclear imaging can detect abnormalities before the onset of the disease and the presence of symptoms in other examination methods because it can show the physiological changes of the organ tissues. This ability to diagnose early often allows the disease to be treated before the disease rapidly progresses.
[0032] The present disclosure also provides a method of making a radioactive microsphere using a heat activation technique. As shown in
[0033] The cooling source is a saturated liquid rich in the liquid phase component of the second seed, and the element of the second seed in the second seed liquid phase component is diffused into the glass spheroid core by the method of dropping and ion diffusion. The second seed plasma is diffused into the surface of a glass sphere core by a heat activation technique to produce a biomedical implant containing a second seed in the diffusion zone of the glass sphere core.
[0034] On the other hand, as shown in
[0035] The surface treatment method of the glass material of the biomedical glass microsphere implant according to the present disclosure mainly causes the second seed element to diffuse into the diffusion region of the glass sphere core by the principle of heat diffusion. For example, the phosphorus ion is thermally chemically diffused. Calcium ions enter the surface of the glass material by means of temperature diffusion, but are not limited thereto.
[0036] In one embodiment, in the second seed used in the present disclosure, the source of the phosphorus ions is to first separate the elements by heating, dissolving or melting phosphorus-containing oxidizing acid or alkali oxide or dissociable salt. A treatment solution containing ions is thus formed. When the surface of the glass material is in contact with the treatment solution under the condition of heat activation, the surface of the glass material is activated as the increased temperature rises, and a large amount of ions in the treatment solution compete for adsorption on the activated surface. At this time, by catalysis of the chemical reaction on the surface, some of the atoms constituting the glass material react and exchange with the ions in the treatment solution, and the ions gradually diffuse into the glass material structure. In the above ion diffusion replacement process, ions with a small ionic radius are affected by the heating temperature, take the lead and gradually diffuse from the surface of the glass into the diffusion region of the glass sphere core. Specifically, the yttrium-containing glass powders are pre-milled and uniformly mixed, and then is heated and sprayed by high-speed gas flame. The glass powder is heated by the high-temperature combustion flame to cause the surface to melt, and the high-temperature molten droplets are formed under influence of the surface tension. During the rotary flight, the high-temperature molten droplets gradually form spherical shape under influence of the air temperature gradient, the gravity and the droplet rotation. As the distance from the flame center increases, the high-temperature molten droplets contact the second seed contained in the cooling source in the end, and because of suddenly reduced temperature gradient, spherical glass microspheres are formed, while the glass ion (yttrium) in the surface of the glass sphere core and the phosphorus ion with smaller ionic radius interact with the second seed in the solution. The ions having the second seed component in the solution diffuse into the glass microsphere material to carry out the temperature diffusion of the calcium ions. At this stage, the ion-containing cooling source, obtained by separating the elements by heating, dissolving or melting the calcium-containing compound, with drastically change of temperature, seal all the ions in the diffusion region of the glass sphere core, allowing them to adjust the surface stress to diffuse into the glass material as the temperature changes. During the process, the calcium ions gradually diffuse into the glass material structure, and as the temperature rises, the ions with smaller ionic radius also diffuse into the glass material beyond the activation energy.
[0037] Since the present disclosure utilizes the method of heating and chemically activating the surface to diffuse the second seed element into the diffusion region of the glass sphere core in the radioactive microsphere, the cold quenching and cooling can be rapidly carried out under controlling the parameters of ion molar concentration and temperature. So that the second seed, e.g., phosphorus and calcium ions, diffusing into the glass sphere core is rapidly sealed into the diffusion zone of the heated and activated glass sphere core, thereby controlling the proportion and diffusion depth of the ions in the formed composite layer. In addition, by further heating the glass material that has been subjected to cold quenching and cooling, the sealed ions can continue to diffuse in the composite layer structure and enter an appropriate cell gap to achieve structural stability.
[0038] In addition, in the surface treatment method of the glass material of the radioactive microsphere of the present disclosure, the second seed such as phosphorus and calcium can directly diffuse into the diffusion region of the glass sphere core. It can also apply heat treatment to the glass material first, allowing oxygen to enter the surface of the glass material to thicken the diffusion region before carrying out the foregoing surface treatment.
[0039] The phosphorus-containing oxidizing acid or the oxidizing base or the dissociable salt used in the present disclosure is not particularly limited as long as it is capable of achieving separation of elements by heating, dissolving or melting to provide needed elements for the surface treatment. It shall be, however, suitable for medical use, e.g., medical inorganic acid. Further, the inorganic salt-containing compound used in the present disclosure is not particularly limited as long as it is capable of achieving separation of elements by heating, dissolving or melting to provide the surface treatment. However, a pharmaceutical grade inorganic salt is better. Preferably, for example, pharmaceutical grade calcium carbonate, calcium acetate, calcium lactate, calcium citrate or the like is applicable.
[0040] The heat activation technique employed in the present disclosure preferably has a temperature in the range of from about 125 C. to about 250 C., preferably, from 165 C. to 175 C. When the heating temperature is lower than 125 C., the reaction solution is not easily observed in the interface; when the heating temperature exceeds 400 C., an unfavorable result of the dimensional change of the glass material may occur.
[0041] The present disclosure illustrates the details by way of examples of the embodiments. However, the interpretation of the present disclosure should not be limited to the following examples. The process conditions of the examples are shown in Table 3.
Example I
[0042] 10 mg of yttrium-containing glass powders as shown in the electron microscope of
Example II
[0043] The preparation method and conditions of Example II were as described in Example I, except that the saturated liquid rich in the second seed liquid phase component is CuSO.sub.4 saturated liquid. Finally, the second seed (Cu ions/S ions) was diffused into the glass sphere core of the radioactive microsphere by a heat activation technique, thereby producing a biomedical implant of a composite layer of a diffusion region extending inwardly from an outer surface of the glass sphere core and containing elements such as the second seed to form a surface microporous glass microsphere, as shown in
Example III
[0044] The preparation method and conditions of the embodiment (3) were as described in Example I, except that the saturated liquid rich in the second seed liquid phase component is CaCl.sub.2 saturated liquid. Finally, the second seed (Ca ions/Cl ions) was diffused into the glass sphere core of the radioactive microsphere by a heat activation technique, thereby producing a biomedical implant of a composite layer of a diffusion region extending inwardly from an outer surface of the glass sphere core and containing elements such as the second seed to form a hollow glass microsphere, as shown in
Example IV
[0045] The preparation method and conditions of Example IV were as described in Example I, except that the saturated liquid rich in the second seed liquid phase component is H.sub.3PO.sub.4 saturated liquid. Finally, the second seed (P ions) was diffused into the glass sphere core of the radioactive microsphere by a heat activation technique, thereby producing a biomedical implant of a composite layer of a diffusion region extending inwardly from an outer surface of the glass sphere core and containing elements such as the second seed to form a solid glass microsphere, as shown in
Example V
[0046] The preparation method and conditions of Example V were as described in Example I, except that the saturated liquid rich in the second seed liquid phase component is TeCl.sub.4 saturated liquid. Finally, the second seed (Te ions/Cl ions) was diffused into the glass sphere core of the radioactive microsphere by a heat activation technique, thereby producing a biomedical implant of a composite layer of a diffusion region extending inwardly from an outer surface of the glass sphere core and containing elements such as the second seed to form a surface microporous glass microsphere, as shown in
Example VI
[0047] The preparation method and conditions of Example VI were as described in Example I, except that the saturated liquid rich in the second seed liquid phase component is ReCl.sub.3 saturated liquid. Finally, the second seed (Re ions/Cl ions) was diffused into the glass sphere core of the radioactive microsphere by a heat activation technique, thereby producing a biomedical implant of a composite layer of a diffusion region extending inwardly from an outer surface of the glass sphere core and containing elements such as the second seed to form a hollow glass microsphere, as shown in
Example VII
[0048] 10 mg of yttrium-containing glass spheres of Example I were taken for spray granulation coating test with different types of organic materials and inorganic materials as shown in Table 2. The relative weight percentage of 0.1 to 10% was set to be uniformly wet-mixed with the sphere (1:1), and then coated by a spray dryer. A flow rate was set at 357 L/h and an outlet temperature was from 180 to 245 C. All of the resulting powder can be coated to form a ball, as shown in
TABLE-US-00001 TABLE 1 Neutron irradiation activation element analysis -ray energy spectrum Test main peak Specific item Radio- energy AUC activity Compound weight isotope (keV) (cnts) Bq (uCi/mg) 1 Y, Na 10 mg Y-90 m 202 264 43.1 0.00012 2 Y, Cu 10 mg Y-90 m 202 410 66.9 0.00018 3 Y, Ca 10 mg Y-90 m 202 393 64.1 0.00017 4 Y, P 10 mg Y-90 m 202 290 47.3 0.00013 5 Y, Te 10 mg I-131 364.5 20 3.9 0.00001 6 Y, Te 10 mg Y-90 m 202 288 47.0 0.00013 7 Y, Re 10 mg Re-188 155.1 1524 1612.7 0.00435 8 Y, Re 10 mg Y-90 m 202 236 38.5 0.00010
TABLE-US-00002 TABLE 2 Organic materials and inorganic materials coating microspheres of Example VII Flow Outlet Weight rate temperature Test coating material percentage (L/h) ( C.) Formability Polyvinylpyrrolidone 0.1-10 357 180-245 Yes (PVP) polyvinyl alcohol (PVA) 0.1-10 357 180-245 Yes Carboxymethyl Cellulose 0.1-10 357 180-245 Yes (CMC) PEG 6000 0.1-10 357 180-245 Yes Methylcellulose (MC) 0.1-10 357 180-245 Yes Hydroxypropyl 0.1-10 357 180-245 Yes methylcellulose (HPMC) Hydroxypropyl cellulose 0.1-10 357 180-245 Yes (HPC) Gum arabic 0.1-10 357 180-245 Yes Methylcellulose (MC) 0.1-10 357 180-245 Yes Copolymer of polylactic 0.1-10 357 180-245 Yes acid and polylactic acid-glycolic acid (PLLA/PLGA) Ca.sub.3(PO.sub.4).sub.s 0.1-10 357 180-245 Yes
TABLE-US-00003 TABLE 3 Reaction parameters and conditions of Examples I to VI Flame composition Flight First seed Second (Mixing ratio of distance from (composed seed oxygen and flame center Microsphere of glass (cooling acetylene) to cooling type Example powders) source) (Nm.sup.3/hr) source) (inch) FIG I yttrium NaCl 1.0~1.5 40 Solid glass saturated microsphere liquid FIG. 2 (E1) II yttrium CuSO.sub.4 1.0~1.5 10 Surface saturated microporous liquid glass microsphere FIG. 2 (E2) III yttrium CaCl.sub.2 1.0~1.5 150 Hollow saturated glass liquid microsphere FIG. 2 (E3) IV yttrium H.sub.3PO.sub.4 1.0~1.5 80 Solid glass saturated microsphere liquid FIG. 2 (E1) V yttrium TeCl.sub.4 1.0~1.5 30 Surface Saturated microporous liquid glass microsphere FIG. 2 (E2) VI yttrium ReCl.sub.3 1.0~1.5 100 Hollow glass saturated microsphere liquid FIG. 2 (E3)